Publications







Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
Atherosclerosis 2017 Aug 15;263:137-144. Epub 2017 Jun 15.
Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States; Department of Medicine, University of Adelaide, Adelaide, Australia; South Australian Health and Medical Research Institute, Adelaide, Australia. Electronic address:

Warfarin Use Is Associated With Progressive Coronary Arterial Calcification: Insights From Serial Intravascular Ultrasound.
JACC Cardiovasc Imaging 2017 Jul 13. Epub 2017 Jul 13.
Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio; Québec Heart and Lung Institute, Québec, Canada; Department of Medicine, University of Adelaide, Adelaide, Australia. Electronic address:


Comparing Coronary Atheroma Progression Rates and Coronary Events in the United States, Canada, Latin America, and Europe.
Am J Cardiol 2016 Dec 31;118(11):1616-1623. Epub 2016 Aug 31.
Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland, Ohio; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. Electronic address:

Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN.
Atherosclerosis 2016 Nov 15;254:78-84. Epub 2016 Sep 15.
C5Research (C5R), Cleveland Clinic, Cleveland, OH, USA; Department of Medicine, University of Adelaide, Adelaide, Australia; Québec Heart & Lung Institute, Québec City, Québec, Canada. Electronic address:

Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events.
Arterioscler Thromb Vasc Biol 2016 Nov 11;36(11):2220-2228. Epub 2016 Aug 11.
From the Cleveland Clinic Coordinating Center for Clinical Research (C5R) (R.P., S.E.N., M.S.), and Department of Cardiovascular Medicine (R.P., S.E.N., M.B.E., S.R.K., E.M.T.), Cleveland Clinic, OH; Department of Medicine, University of Adelaide, Australia (R.P., S.J.N.); and South Australian Health and Medical Research Institute, Adelaide, Australia (Y.K., S.J.N.).

Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
Am J Cardiol 2016 Sep 15;118(5):647-55. Epub 2016 Jun 15.
Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, Ohio; Hôpital Laval, Québec Heart and Lung Institute, Québec, Québec, Canada. Electronic address:

Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease.
Circ Cardiovasc Imaging 2016 Aug;9(8)
From the South Australian Health & Medical Research Institute, University of Adelaide, Australia (Y.K., P.K., S.J.N.); Department of Cardiovascular Medicine, Cleveland Clinic, OH (R.P., M.H., B.D., K.U., S.R.K., E.M.T.); and Cleveland Clinic Coordinating Center for Clinical Research, OH (R.P., K.U., S.E.N.).

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Am Heart J 2016 Jun 17;176:83-92. Epub 2016 Feb 17.
Cleveland Clinic Coordinating Center for Clinical Research (C5R), Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; Department of Medicine, University of Adelaide, Adelaide, Australia; South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia. Electronic address:





Non-invasive volumetric assessment of aortic atheroma: a core laboratory validation using computed tomography angiography.
Int J Cardiovasc Imaging 2016 Jan 12;32(1):121-9. Epub 2015 May 12.
Atherosclerosis Imaging Core Laboratory, Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, 44195, USA.

Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
Atherosclerosis 2015 Dec 20;243(2):553-9. Epub 2015 Oct 20.
Department of Medicine, University of Adelaide, Adelaide, Australia; South Australian Health and Medical Research Institute, Adelaide, Australia. Electronic address:


Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque: A Combined Pathological and In Vivo Study.
Arterioscler Thromb Vasc Biol 2015 Nov 3;35(11):2423-31. Epub 2015 Sep 3.
From the Cleveland Clinic Coordinating Center for Clinical Research (C5R) (R.P., K.W., K.L.K., K.U., S.E.N.), and Department of Cardiovascular Medicine (R.P., S.R.K., E.M.T., S.E.N.), Cleveland Clinic, OH; Department of Medicine, University of Adelaide, South Australia (R.P., S.J.N.); Frederik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI (R.D.M.); InfraRedX Inc., Burlington, MA (S.P.M., S.T.S., J.E.M.); South Australian Health and Medical Research Institute, Adelaide, South Australia (J.A., Y.K., S.J.N.); CVPath Institute, Gaithersburg, MD (R.V.); and Cardiovascular Research Foundation, New York, NY (A.M., G.S.M.).


Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.
Circ Arrhythm Electrophysiol 2015 Aug 10;8(4):772-6. Epub 2015 Jun 10.
From the Minneapolis Heart Institute, MN (J.M.A.); Department of Cardiovascular Medicine, Cleveland Clinic, OH (W.I.S., M. Bhargava, M. Bassiouny, D.J., B.L., M.M., S.E.N., S.P., C.T.-E., K.W., B.L.W.); Brown University, Providence, RI (C.V.); and Department of Internal Medicine, Johns Hopkins Hospital, Baltimore, MD (D.L.).



Atheroma progression in hyporesponders to statin therapy.
Arterioscler Thromb Vasc Biol 2015 Apr 26;35(4):990-5. Epub 2015 Feb 26.
From the South Australian Health and Medical Research Institute, Heart Health Theme, University of Adelaide, Adelaide, Australia (Y.K., S.J.N.); and C5 Research (J.S.J., K.W., K.U., R.P., S.E.N.) and Department of Cardiovascular Medicine, Heart and Vascular Institute (R.P., E.M.T., S.E.N.), Cleveland Clinic, OH.

Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis.
Cardiovasc Diagn Ther 2014 Dec;4(6):460-9
1 South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia ; 2 Cleveland linic Coordinating Center for Clinical Research, Cleveland, Ohio, USA ; 3 Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.


Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
Arterioscler Thromb Vasc Biol 2014 Nov 11;34(11):2465-72. Epub 2014 Sep 11.
From the Department of Cardiovascular Medicine (R.P., S.E.N.) C5Research (R.P., S.E.N., M.S., S.J.N.), Cleveland Clinic, OH; Section of Cardiovascular Research, Baylor College of Medicine, and the Methodist DeBakey Heart and Vascular Center, Houston, TX (C.M.B.); Centre for Vascular Research, University of New South Wales, Sydney, New South Wales, Australia (P.J.B.); INSERM Dyslipidaemia and Atherosclerosis Research Unit, Pitié-Salpetriere University Hospital, Paris, France (M.J.C.); West German Heart Center, Essen, Germany (R.E.); Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (P.L.); AstraZeneca, Wilmington, DE (J.S.R.); and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia (K.U., Y.K., S.J.N.).

Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
JACC Cardiovasc Imaging 2014 Oct 17;7(10):1013-22. Epub 2014 Sep 17.
C5Research, Cleveland Clinic, Cleveland, Ohio; South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia. Electronic address:

Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy.
Am J Cardiol 2014 Aug 6;114(4):549-54. Epub 2014 Jun 6.
Heart Health, South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia.

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study.
Lancet Diabetes Endocrinol 2014 Jun 18;2(6):455-63. Epub 2014 Feb 18.
Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands. Electronic address:

Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes.
N Engl J Med 2014 May 31;370(21):2002-13. Epub 2014 Mar 31.
From the Bariatric and Metabolic Institute (P.R.S., S.A.B., A.A.), Lerner Research Institute (J.P.K.), Heart and Vascular Institute (K.W., C.E.P., E.S.H.K., S.E.N.), Urological and Kidney Institute (S.D.N.), and Endocrinology Institute (S.R.K.), Cleveland Clinic, Cleveland; and Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School - both in Boston (D.L.B.).


Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound.
Atherosclerosis 2014 Feb 19;232(2):377-83. Epub 2013 Dec 19.
Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.


C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Circulation 2013 Nov 16;128(22):2395-403. Epub 2013 Sep 16.
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH (R.P., S.E.N., K.U., Y.K., S.J.N.); Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (P.L.); C5Research, Cleveland Clinic, Cleveland, OH (M.S.); Section of Cardiovascular Research, Baylor College of Medicine, and the Methodist DeBakey Heart and Vascular Center, Houston, TX (C.M.B.); Centre for Vascular Research, University of New South Wales, Sydney, Australia (P.J.B.); INSERM Dyslipidaemia and Atherosclerosis Research Unit, Hôpital de la Pitié, Paris, France (M.J.C.); West German Heart Center, Essen, Germany (R.E.); AstraZeneca, Wilmington, DE (J.S.R.); and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia (S.J.N.).


Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
N Engl J Med 2013 Oct 2;369(14):1327-35. Epub 2013 Sep 2.
Calhoun Cardiology Center, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Ave., Farmington, CT 06030-3940, USA.




Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med 2016 07 13;375(4):311-22. Epub 2016 Jun 13.
From the University of Texas Southwestern Medical Center, Dallas (S.P.M.); Massachusetts General Hospital, Boston (G.H.D.); Novo Nordisk, Bagsvaerd, Denmark (K.B.-F., P.K., L.S.R., M.S.); Friedrich Alexander University of Erlangen, Erlangen (J.F.E.M.), and St. Josef Hospital, Ruhr University, Bochum (M.A.N.) - both in Germany; Cleveland Clinic, Cleveland (S.E.N.); London School of Hygiene and Tropical Medicine Medical Statistics Unit (S.P.) and Imperial College London (N.R.P.), London; George Washington University Medical Center, Washington, DC (W.M.S.); Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); International Diabetes Center at Park Nicollet, Minneapolis (R.M.B.); and the University of North Carolina School of Medicine, Chapel Hill (J.B.B.).

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
Hypertension 2016 09 1;68(3):606-13. Epub 2016 Aug 1.
From the Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Takeda Development Center Americas, Inc, Deerfield, IL (C.A.W., S.K.); University of Chicago Medicine, IL (G.L.B.); International Diabetes Center, Park-Nicollet Clinic, Minneapolis, MN (R.M.B.); Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.P.C.); Memphis Veterans Affairs Medical Center, University of Tennessee College of Medicine (W.C.C.); University of Sheffield, United Kingdom (S.K.H.); Harvard School of Public Health, Boston, MA (C.R.M.); Cleveland Clinic Foundation, OH (S.E.N.); and Université de Lorraine, Nancy, France (F.Z.).


Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
N Engl J Med 2016 12 13;375(26):2519-29. Epub 2016 Nov 13.
From the Cleveland Clinic, Cleveland (S.E.N., M.E.H., L.M.W., K.E.W., Q.W., V.M., A.M.L.); Western Sydney University, Campbelltown, NSW, Australia (N.D.Y.); Brigham and Women's Hospital, Harvard Medical School, Boston (D.H.S., P.L.); University Hospital Zurich, Zurich, Switzerland (T.F.L., F.R.); Baylor College of Medicine, Veterans Affairs Medical Center, Houston (D.Y.G.); and State University of New York, Downstate Health Sciences Center (J.S.B.) and Pfizer (M.G., B.B., M.F.B., W.B.), New York.


Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.
N Engl J Med 2017 02;376(7):641-651
From the Bariatric and Metabolic Institute (P.R.S., A.A., S.A.B.), Lerner Research Institute (J.P.K.), Cleveland Clinic Coordinating Center for Clinical Research (K.W., C.E.P., S.E.N.), Cole Eye Institute (R.P.S.), and Endocrinology Institute (S.R.K.), Cleveland Clinic, Cleveland; Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); and the Section of Nephrology, Baylor College of Medicine, Houston (S.D.N.).

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
N Engl J Med 2017 05;376(20):1933-1942
From the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland (A.M.L., V.M., E.M., K.W., D.M., S.E.N.); South Australian Heart and Medical Research Institute, University of Adelaide, Adelaide (S.J.N.), and School of Medical Sciences, University of New South Wales, Sydney (P.J.B.) - both in Australia; Eli Lilly, Indianapolis (J.S.R., G.R., B.V., G.W.); Washington Cardiovascular Associates, Medstar Research Institute, Washington, DC (H.B.B.); Centre for Cardiovascular Science, University of Edinburgh, Edinburgh (K.A.A.F.); Beth Israel Deaconess Medical Center, Boston (C.M.G.); Duke University Medical Center, Durham, NC (C.G.); Université Sorbonne Paris 6, ACTION Study Group, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Institut de Cardiologie, Paris (G.M.); Penn Heart and Vascular Center, Philadelphia (D.R.); Columbia University, New York (A.R.T.), and Saratoga Cardiology Associates, Saratoga Springs (D.K.) - both in New York; St. Michael's Hospital, Toronto (S.G.), Recherche Médicale Saint-Jérôme, Saint-Jérôme, QC (Y.P.), and Centre de Santé et de Services Sociaux du Nord de Lanaudière-Centre Hospitalier Régional de Lanaud, Saint-Charles-Borromée, QC (S.K.) - all in Canada; Instituto Cardiovascular de Buenos Aires, Buenos Aires (D.C.); University of Texas Southwestern Medical Center, Dallas (D.K.M.); Heart Institute (InCor)-University of São Paulo Medical School, São Paulo (J.C.N.); Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosi, Mexico (J.L.L.-P.); the First Affiliated Hospital of Harbin Medical University, Harbin, China (W.L.); and South Oklahoma Heart Research, Oklahoma City (N.T.).

OF